Highlights

  • NUZ-001 is enrolled in the 250-participant Phase 2/3 HEALEY ALS Platform Trial, with database lock expected in Q2 CY2027 and topline results expected in late Q2 CY2027.
  • The trial achieved record enrolment for the HEALEY platform, with 250 participants enrolled in under five months.
  • FDA Type C feedback indicated that positive HEALEY results could potentially support a traditional US approval pathway for NUZ-001.
  • The company is fully funded through to the HEALEY topline readout, with outstanding convertible notes redeemed and a recent AUD 4.3 million Placement completed.

Neurizon Therapeutics Limited (ASX:NUZ) presented at the Bell Potter Healthcare Conference in November 2026, providing a comprehensive update on its lead programme, NUZ-001, an investigational oral therapy for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease. NUZ-001 is currently enrolled in Regimen I of the HEALEY ALS Platform Trial at Massachusetts General Hospital, a 250-participant randomised Phase 2/3 study. Topline results are expected in late Q2 CY2027. The company is fully funded through to that readout, with no convertible notes currently on issue.

Disease Context and Mechanism of Action

ALS is a rapidly progressive neurodegenerative disease characterised by the loss of voluntary muscle function, affecting speech, swallowing, movement, and breathing. The typical time from diagnosis to end of life is two to five years, and there is no approved therapy that has substantially altered disease progression for the broad patient population. Approximately 35,000 people are living with ALS in the United States alone. The unmet need is substantial and has attracted significant pharmaceutical and biotech Investment in recent years.

NUZ-001 targets TDP-43 aggregation — a pathological feature shared by approximately 97% of ALS cases — through enhancement of cellular protein clearance mechanisms, including autophagy and the proteasomal system. TDP-43 dysfunction leads to loss of normal nuclear function and accumulation of toxic cytoplasmic aggregates, disrupting axon maintenance and the motor neuron-muscle connection. Preclinical studies have demonstrated that NUZ-001 prevents TDP-43 aggregation, enhances protein clearance pathways, preserves neuronal health markers, and restores synaptic signalling in ALS models.

Trial Design and Phase 1 Signals

Regimen I is a double-blind, placebo-controlled adaptive Phase 2/3 trial under the HEALEY master protocol at Massachusetts General Hospital. The original 160-participant design was expanded to 250 participants in May 2026, with no impact on funding. Enrolment was completed in July 2026, with all participants dosed and the 36-week blinded treatment period underway. The trial uses a fully concurrent internal placebo arm, removing the temporal drift and comparability limitations associated with pooled historical placebos. The primary endpoints are change in the ALSFRS-R functional score and survival from baseline to week 36.

Phase 1 and open-label extension data collected from twelve patients provided preliminary signals of efficacy. When compared with matched controls from the PRO-ACT historical database, treatment with NUZ-001 was associated with a 31% slowing in ALSFRS-R decline and a 43% slowing in respiratory decline (SVC). An analysis of survival data suggested a statistically significant improvement in survival. These signals, while from a small and uncontrolled sample, informed the design and expansion of the Phase 2/3 programme and are consistent with the preclinical mechanistic rationale.

Funding Position and Strategic Optionality

Neurizon has simplified its Capital Structure ahead of the HEALEY topline readout. Outstanding convertible notes have been redeemed, reducing selling pressure and overhang. A recent AUD 4.3 million placement was completed with new and existing investors, and the company has launched a share purchase plan targeting AUD 2 million, with one free option per share subscribed at 6.8 cents (options exercisable at AUD 0.12, 18 months, subject to Shareholder approval). The company is fully funded through to the topline readout, including one further potential Facility drawdown after April 2027 if needed.

The company also holds an FDA Orphan Drug Designation for NUZ-001 in ALS. FDA Type C feedback indicated that positive HEALEY results could potentially support a traditional US approval pathway. A US NIH-funded Expanded Access Program for up to 200 participants is planned for 2027, adding long-term safety and real-world data. The comparable transaction benchmark cited by the company is Shionogi's Acquisition of RADICAVA global rights for approximately USD 2.5 billion, noting the significant value that successful ALS treatments have commanded.

Key Insights

The HEALEY topline readout in late Q2 CY2027 is the defining near-term event for Neurizon, representing the first randomised efficacy data for NUZ-001 and the catalyst that will determine the company's regulatory, partnering, and commercial strategy.

The simplification of the capital structure — with convertible notes redeemed and no further dilution expected from that source — reduces the overhang ahead of the readout and signals management's confidence in the existing funding runway.

Preclinical and Phase 1 signals, combined with FDA Type C feedback indicating a potential traditional approval pathway on positive results, provide a foundation for the clinical investment thesis ahead of the pivotal readout.